Canadian Glycomics Network (GlycoNet) - Clinical Partnerships 2022–2023

The Canadian Glycomics Network (GlycoNet) is a Network of Centres of Excellence (NCE) that focuses on the role of glycans (carbohydrates) in health. Areas of focus are infectious diseases, chronic diseases, cancer, and neurodegenerative diseases.

In this Request for Proposals, GlycoNet is seeking to fund Clinical Partnership projects that would offer clinicians and biomedical researchers opportunities to partner with Network Investigators to study glycans or glycosylation changes in disease. This partnership would increase clinician awareness of the role of glycomics in disease, and expand glycomics translational research and its application in more problems of clinical importance. Partnership outcomes could be better understanding of disease, drug development strategies, or new drug targets.

Projects should:

• Be aligned with one of the GlycoNet research themes (see glyconet.ca) and be targeted to a specific disease.

• Be of an applied nature so that after additional funding through other means, the outcomes could lead to novel treatments for disease.

• Involve the training of Highly Qualified Personnel.

• Involve two research groups with one clinical or biomedical group. Examples of Clinical Partnership project could be the validation of the changes of a glycan with biobank samples in a specific disease. It is anticipated that the large majority of the funding will be directed to the clinician group. Although not required, partner funding would be an asset.

AVAILABLE FUNDING

GlycoNet has set aside up to $150,000 annually for this competition. Proposals may request up to $50,000 in funding.

ELIGIBILITY

Based on NCE requirements, this opportunity is open only to individuals who are eligible to hold Tri-Council funds; i.e., the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC) or the Social Sciences and Humanities Research Council of Canada (SSHRC). Furthermore, GlycoNet requires that all investigators receiving Network funding must have other peer-reviewed support. Such support need not be from the Tri-Council.

Questions about project suitability can be directed to info@glyconet.ca.

HOW TO APPLY

Potential applicants must register by email to info@glyconet.ca. Please provide the project title, anticipated budget request, and list of investigators involved in the project. This information is not binding and can change when the application is submitted. Upon registration, applicants will receive instructions for completing the application. Applications will be reviewed on a quarterly basis. 

DEADLINES

This is a rolling call. There are quarterly reviews until the funds are fully allocated. Applicants can submit their proposals when they are ready. Application review will be performed as follow:

• April 10 deadline: Results expected by July 2

• July 2 deadline: Results expected by October 1

• October 1 deadline: Results expected by January 2

• January 2 deadline: Results expected by April 1

Additional Information Questions about this opportunity can be sent to  info@glyconet.ca.

WEBSITE

https://canadianglycomics.ca/wp-content/uploads/Request-for-Proposals-Clinical-Partnerships-2022-23.pdf

SFU Signature Sheet is due to ORS 3 business days before the agency deadline. 

 

 

Upcoming Deadlines

External
Internal
July 01, 2022July 01, 2022 Verified Date
June 29, 2022 Jun. 29, 2022 June 29, 2022 16:00:00 June 29, 2022 16:00:00 America/Vancouver Application Deadline: Canadian Glycomics Network (GlycoNet) - Clinical Partnerships 2022–2023 In this Request for Proposals, the Canadian Glycomics Network (GlycoNet) is seeking to fund Clinical Partnership projects that would offer clinicians and biomedical researchers opportunities to partner with Network Investigators to study glycans or glycosylation changes in disease. This partnership would increase clinician awareness of the role of glycomics in disease, and expand glycomics translational research and its application in more problems of clinical importance. Partnership outcomes could be better understanding of disease, drug development strategies, or new drug targets. .

x